ABSTRACT
Acute promyelocytic leukemia (APL) is characterized by the PML -RARA fusion gene. To identify genetic changes that cooperate with PML-RARA, we performed spectral karyotyping analysis of myeloid leukemias from transgenic PML-RARA mice, and from mice coexpressing PML-RARA and BCL2, IL3, activated IL3R, or activated FLT3. A cooperating mutation that enhanced survival (BCL2)
was not sufficient to complete transformation, and was associated with multiple numerical abnormalities, whereas cooperating mutations that deregulated growth and enhanced survival were associated with normal karyotypes (IL3) or simple karyotypic changes (IL3R, FLT3). Recurring abnormalities included trisomy 15 (49%), trisomy 8 (46%), and -X/-Y (54%). The most common secondary abnormality in human APL is +8 or partial trisomy of 8q24, syntenic to mouse 15 8, 9 , IL3 (pMPZen-IL-3) 10, 11 , or an activated IL3R ( cV449E) 11, 12 , respectively.
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Spectral Karyotyping (SKY) Analysis. Cytogenetic analysis was performed on fresh or cryopreserved spleen or bone marrow cells obtained at the time of development of leukemia. The initiation of short-term (24-72 hours) cultures, metaphase cell preparation, and spectral karyotyping were performed as described previously. 13 A minimum of 10 metaphase cells were analyzed per leukemia.
RESULTS AND DISCUSSION
Cytogenetic Analysis of Murine Leukemias Initiated by PML-RARA. The results of SKY analysis and features of the murine leukemias are given in Table 1 . The distribution of chromosome abnormalities in the genetic cohorts is illustrated in Figure 1 ; the complete karyotypes are provided on the laboratory's website (http://LeBeauLab.uchicago.edu, Table D) , and in previous reports. 9, 11, 13 Each of the additional mutations cooperated with PML-RARA, as evidenced by the increase in leukemia incidence from 64% to between 70-100%, and the decrease in latency period from 257 days to between 14-127 days. The incidence of clonal chromosomal abnormalities was high, ranging from 80-100% of cases, in all but the cohort expressing PML-RARA and IL3, in which all cases had a normal karyotype.
The most common abnormality was loss of a sex chromosome, an X in females or a Y chromosome in males, noted in 22/41 cases (54%). A gain of chromosome 15 was observed in 20 (49%) cases, and trisomy 8 was observed in 19 (46%) cases.
Of the 11 cases analyzed in PML -RARA transgenic mice, clonal abnormalities were identified in 10 (91%). The most common abnormality was a gain of chromosome 15 (7 cases, 64%) ( Figure 1A ).
Loss of a sex chromosome was noted in six cases (55%), and trisomy 8 was observed in five (45%)
cases.
BCL2 is expressed in most APLs. 14 In the PML-RARA/BCL2 cohort, all leukemias had a complex karyotype, and were characterized by multiple abnormal clones with multiple numerical abnormalities in each clone (Table 1, Figure 1B ). All but two cases had 45 chromosomes in the abnormal clone(s), as compared to 1/11 leukemias arising in PML -RARA mice, and none in the other genetic cohorts. All eight cases were characterized by trisomy 15 (100%). Of interest is that six of eight cases had the identical pattern of +4, +7, +10, and +15.
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The FLT3 receptor tyrosine kinase enhances the proliferation and survival of hematopoietic progenitors in response to the FLT3 ligand. Activating FLT3 mutations have been identified in ~35% of APLs, most of which result from an internal tandem duplication (ITD) of the juxtamembrane domain. 15 All of the leukemias arising in the PML-RARA/FLT3 W51 mice had abnormal karyotypes;
however, the karyotypes were very simple with 6 of 7 (86%) showing loss of an X chromosome, together with either +10 or +15 (each in 3 of 7 cases, 43%) ( Figure 1C ). 9 Activating mutations of the common chain of the IL3, IL5, and GM-CSF receptors confer cytokine independence. 10, 12 In the PML-RARA/IL3R ( cV449E) leukemias, 7 of 9 cases (78%) were abnormal, with simple karyotypes. Trisomy 8 (7 of 9 cases, 78%) was most common, followed by loss of an X chromosome (4 of 9 cases, 44%), and trisomy 15 (2 of 9 cases, 22%) ( Figure 1D ). 11 We have reported that complete trisomy 8 or partial trisomy of bands 8q23-24 (12.4%) are the most common secondary chromosomal abnormalities in human APL. 13 Trisomy 15 is the most frequent abnormality in murine T cell lymphomas (40-90%), as well as in B/myeloid leukemias arising in irradiated Eµ-BCL2 transgenic mice. 16, 17 The smallest region gained is bands 15D2-3; this region is syntenic to human 8q23-24, and contains the Myc and Pvt1 genes. 17 At present, the identity of the relevant gene(s) on human 8q is unknown; however, AMLs characterized by trisomy 8 overexpress genes on chromosome 8, suggesting that gene dosage effects mediate leukemogenesis. 18 Perhaps the best candidate gene is MYC, which is overexpressed in a number of human tumors.
Genetic Pathways to APL.
We have demonstrated that the particular combination of cooperating events leads to an obligate pattern of additional mutations that complete transformation. The initiating event, the PML-RARA fusion protein, impairs differentiation; however, leukemogenesis requires additional mutations. The addition of a cooperating mutation that enhances survival, such as BCL2 expression, is not sufficient to complete transformation, and is associated with instability and the acquisition of multiple numerical abnormalities. 
